Market Overview

UPDATE: Ascendiant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results

Related RPRX
Repros Holds Meeting With FDA, Says It Is Clear FDA No Closed To Entering Secondary Hypogonadism As An Indication
Repros Updates Proellex Program

In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX), and raised the price target from $23.00 to $25.00.

In the report, Ascendiant Capital Markets noted, “We believe that the positive result from the ZA-305 study bodes well for a positive result from the ZA-304 study, given that the trials are identical in design. Further, we believe that positive results from these studies will also be valuable in supporting potential labeling claims for superiority of Androxal over Androgel, which would improve the commercial attractiveness of the product. Our 12 month PT is calculated using an NPV analysis.”

Repros Therapeutics closed on Thursday at $18.21.

Latest Ratings for RPRX

Dec 2015Brean CapitalTerminatesBuy
Oct 2015Brean CapitalDowngradesBuyHold
Oct 2015Bank of AmericaDowngradesNeutralUnderperform

View More Analyst Ratings for RPRX
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital Markets Keay NakaeAnalyst Color Price Target Analyst Ratings


Related Articles (RPRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters